La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Eisai Gestione

Gestione criteri di controllo 1/4

Eisai's Il CEO è Haruo Naito, nominato in Jun2003, ha un mandato di 21.17 anni. possiede direttamente 0.23% delle azioni della società, per un valore di ¥ 3.89B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.6 anni e 2.2 anni.

Informazioni chiave

Haruo Naito

Amministratore delegato

JP¥211.0m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	21.2yrs
Proprietà del CEO	0.2%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	2.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Haruo Naito rispetto agli utili di Eisai?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	JP¥33b
Mar 31 2024	JP¥211m	n/a	JP¥42b
Dec 31 2023	n/a	n/a	JP¥45b
Sep 30 2023	n/a	n/a	JP¥48b
Jun 30 2023	n/a	n/a	JP¥49b
Mar 31 2023	JP¥157m	n/a	JP¥55b
Dec 31 2022	n/a	n/a	JP¥27b
Sep 30 2022	n/a	n/a	JP¥32b
Jun 30 2022	n/a	n/a	JP¥33b
Mar 31 2022	JP¥127m	JP¥89m	JP¥48b
Dec 31 2021	n/a	n/a	JP¥57b
Sep 30 2021	n/a	n/a	JP¥63b
Jun 30 2021	n/a	n/a	JP¥60b
Mar 31 2021	JP¥125m	JP¥89m	JP¥42b
Dec 31 2020	n/a	n/a	JP¥94b
Sep 30 2020	n/a	n/a	JP¥121b
Jun 30 2020	n/a	n/a	JP¥125b
Mar 31 2020	JP¥157m	JP¥89m	JP¥122b
Dec 31 2019	n/a	n/a	JP¥97b
Sep 30 2019	n/a	n/a	JP¥58b
Jun 30 2019	n/a	n/a	JP¥73b
Mar 31 2019	JP¥152m	JP¥89m	JP¥63b

Compensazione vs Mercato: La retribuzione totale di Haruo ($USD 1.44M ) è circa la media per le aziende di dimensioni simili nel mercato JP ($USD 1.64M ).

Compensazione vs guadagni: La retribuzione di Haruo è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Haruo Naito (77 yo)

21.2yrs

Mandato

JP¥211,000,000

Compensazione

Mr. Haruo Naito has been the Chief Executive Officer of Eisai Co., Ltd. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President and Representative Di...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Haruo Naito	CEO, Representative Corporate Officer & Director	21.2yrs	JP¥211.00m	0.23% ¥ 3.9b
Gary Hendler	Senior VP & President of EMEA Region	no data	JP¥218.00m	Nessun dato
Lynn D. Kramer	VP & Chief Clinical Officer	no data	JP¥297.00m	Nessun dato
Yanhui Feng	Senior Vice President	4.6yrs	JP¥189.00m	Nessun dato
Mitsuru Shomon	VP & CFO	1.1yrs	Nessun dato	Nessun dato
Keisuke Naito	Representative Corporate Officer	less than a year	Nessun dato	Nessun dato
Makoto Hoketsu	VP & Chief Information Officer	less than a year	Nessun dato	Nessun dato
Masatomi Akana	Senior VP	1.6yrs	Nessun dato	Nessun dato
Shin Kato	VP, General Counsel & Chief Compliance Officer	less than a year	Nessun dato	Nessun dato
Sayoko Sasaki	Vice President of Corporate Communications & Sustainability	2.6yrs	Nessun dato	Nessun dato
Teruyuki Masaka	VP, Chief HR Officer & Corporate Officer of General Affairs Japan Subsidiaries	2.6yrs	Nessun dato	Nessun dato
Takashi Owa	Senior VP & Chief Scientific Officer - Japan Medical Safety	no data	Nessun dato	Nessun dato

1.6yrs

Durata media

56.5yo

Età media

Gestione esperta: Il team dirigenziale di 4523 non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Haruo Naito	CEO, Representative Corporate Officer & Director	10.2yrs	JP¥211.00m	0.23% ¥ 3.9b
Yuko Yasuda	Outside Independent Director	1.2yrs	Nessun dato	0.000020% ¥ 334.3k
Fumihiko Ike	Independent Outside Chairman	3.2yrs	Nessun dato	0.00035% ¥ 5.9m
Toru Moriyama	Outside Independent Director	1.2yrs	Nessun dato	0.00016% ¥ 2.7m
Kenta Takahashi	Director	less than a year	Nessun dato	0.0039% ¥ 64.9m
Ryota Miura	Independent Outside Director	3.2yrs	Nessun dato	0.00032% ¥ 5.3m
Hiroyuki Kato	Director	2.2yrs	Nessun dato	0.0030% ¥ 49.8m
Yoshiteru Kato	Director	3.2yrs	Nessun dato	0.0038% ¥ 62.8m
Yumiko Miwa	Independent Outside Director	4.2yrs	Nessun dato	0.00043% ¥ 7.2m
Richard Thornley	Outside Independent Director	2.2yrs	Nessun dato	Nessun dato
Takuji Kanai	Independent Outside Director	less than a year	Nessun dato	Nessun dato

2.2yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 4523 non è considerato esperto (durata media del mandato 2.2 anni), il che suggerisce un nuovo consiglio.

Eisai Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new directors

High number of new directors

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Recent updates

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

New minor risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 17%

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

New minor risk - Share price stability

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Is Eisai (TSE:4523) A Risky Investment?

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Final dividend of JP¥80.00 announced

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Consensus EPS estimates increase by 10%, revenue downgraded

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

High number of new directors

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Now 21% overvalued

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.

Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of JP¥80.00 per share at 1.9% yield

NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study

New minor risk - Share price stability

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea

Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Consensus EPS estimates fall by 25%

Now 21% undervalued

Upcoming dividend of JP¥80.00 per share at 2.2% yield

Third quarter 2023 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente